2,3-Dichloro-5-(trifluoromethyl)pyridine

We are 2,3-Dichloro-5-(trifluoromethyl)pyridine CAS:69045-84-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,3-Dichloro-5-(trifluoromethyl)pyridine
CAS.NO:69045-84-7
Synonyms:2,3-Dichloro-5-(trifluoromethyl)pyridine
2,3-dichloro-5-trifluoropyridine
2,3-dichloro-5-trifluoromethylpyridine
5-trifluoromethyl-2,3-dichloropyridine
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 188.5±35.0 °C at 760 mmHg
Melting Point 8-9 °C
Molecular Formula C6H2Cl2F3N
Molecular Weight 215.988
Flash Point 79.4±0.0 °C
Vapour Pressure 0.8±0.3 mmHg at 25°C
Index of Refraction 1.470
 
Specification:
Appearance:Colorless to light yellow transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Chlorfluazuron(CAS:71422-67-8) and Fluazuron(CAS:86811-58-7).

2,3-Dichloro-5-(trifluoromethyl)pyridine


Related News: In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.61-19-8 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Bromuro de 4-fenoxibutilo CAS:1200-03-9 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.3-Amino-2,2-dimethylpropanamide CAS:324763-51-1 For example, an active ingredient to relieve pain is included in a painkiller.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Related Products
Product Name
1-Fluoro-2-nitrobenzene View Details
2,6-Dichloropurine-9-b-D-riboside View Details
D-Proline View Details
4-Butylphenylboronic acid manufacturer 2,4-Difluorotoluene manufacturer 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea,hydrochloride manufacturer 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester manufacturer 1-bromo-4-iodobutane manufacturer